Response to rituximab by number of prior therapies and prior therapy response
. | . | . | . | . | Bone marrow HCs, % . | . | . | Bone marrow flow cytometry CD20, % . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | No. of prior treatments . | Prior response* . | Rituximab response (no. of doses)† . | RR, % (response) . | Before therapy . | After therapy . | Immuno/cytochemical marrow stains after therapy . | Before therapy . | After therapy . | ||
| 1 | 3 | CR | CR | 53 (CR) | 11 | 0 | Rare TRAP+ CD20— | 95.7 | 0.8 | ||
| 2 | 3 | NR‡ | CR | 3 | 0 | TRAP— CD20— | 78.4 | 0.0 | |||
| 3 | 1 | CR | CR | 18 | 0 | Rare TRAP+ | 49.2 | 0.0 | |||
| 4 | 1 | CR | CR | 5 | 0 | Rare TRAP+ | 59.9 | ND | |||
| 5 | 1 | CR | CR | 7 | 0 | TRAP— Pax-5+ 9% | 76.7 | 1.8 | |||
| 6 | 1 | CR | CR | 6 | 0 | Rare TRAP+ Pax-5+ 10% | 87.3 | 0.2 | |||
| 7 | 1 | NR‡ | CR | 5 | 0 | Rare TRAP+ Pax-5+ 11% | 85.1 | 3.1 | |||
| 8 | 2 | NR‡ | CR (12) | 10 | 0 | Rare TRAP+ Pax-5+ 14% | 95.4 | 1.4 | |||
| 9 | 8 | PR | CR-RD | 13 (CR-RD) | 22 | 4 | ND | 96.2 | 0.8 | ||
| 10 | 4 | NR | CR-RD (4) | 24 | 2 | ND | 91.8 | ND | |||
| 11 | 1 | CR | PR (4) | 13 (PR) | 33 | 7 | ND | 89.6 | 4.6 | ||
| 12 | 2 | NR‡ | PR (12) | 15 | 4 | ND | 87.2 | 67.5 | |||
| 13 | 1 | NR‡ | NR | 20 (NR) | 30 | 28 | ND | 88.5 | 91.3 | ||
| 14 | 3 | CR | NR (6) | 71 | 90 | ND | 93.5 | 0.4 | |||
| 15 | 4 | PR | NR (4) | 7 | 17 | ND | 88.4 | ND | |||
. | . | . | . | . | Bone marrow HCs, % . | . | . | Bone marrow flow cytometry CD20, % . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | No. of prior treatments . | Prior response* . | Rituximab response (no. of doses)† . | RR, % (response) . | Before therapy . | After therapy . | Immuno/cytochemical marrow stains after therapy . | Before therapy . | After therapy . | ||
| 1 | 3 | CR | CR | 53 (CR) | 11 | 0 | Rare TRAP+ CD20— | 95.7 | 0.8 | ||
| 2 | 3 | NR‡ | CR | 3 | 0 | TRAP— CD20— | 78.4 | 0.0 | |||
| 3 | 1 | CR | CR | 18 | 0 | Rare TRAP+ | 49.2 | 0.0 | |||
| 4 | 1 | CR | CR | 5 | 0 | Rare TRAP+ | 59.9 | ND | |||
| 5 | 1 | CR | CR | 7 | 0 | TRAP— Pax-5+ 9% | 76.7 | 1.8 | |||
| 6 | 1 | CR | CR | 6 | 0 | Rare TRAP+ Pax-5+ 10% | 87.3 | 0.2 | |||
| 7 | 1 | NR‡ | CR | 5 | 0 | Rare TRAP+ Pax-5+ 11% | 85.1 | 3.1 | |||
| 8 | 2 | NR‡ | CR (12) | 10 | 0 | Rare TRAP+ Pax-5+ 14% | 95.4 | 1.4 | |||
| 9 | 8 | PR | CR-RD | 13 (CR-RD) | 22 | 4 | ND | 96.2 | 0.8 | ||
| 10 | 4 | NR | CR-RD (4) | 24 | 2 | ND | 91.8 | ND | |||
| 11 | 1 | CR | PR (4) | 13 (PR) | 33 | 7 | ND | 89.6 | 4.6 | ||
| 12 | 2 | NR‡ | PR (12) | 15 | 4 | ND | 87.2 | 67.5 | |||
| 13 | 1 | NR‡ | NR | 20 (NR) | 30 | 28 | ND | 88.5 | 91.3 | ||
| 14 | 3 | CR | NR (6) | 71 | 90 | ND | 93.5 | 0.4 | |||
| 15 | 4 | PR | NR (4) | 7 | 17 | ND | 88.4 | ND | |||
RR indicates response rate; HCs, hairy cells; CR, complete response; TRAP, tartrate-resistant acid phosphatase stain; —, _____; NR, no response; ND, not done; PR, partial response; and CR-RD, CR with residual marrow hairy cells 1% to 5%.
Response to last therapy received prior to rituximab
Fewer than 8 doses due to patient request, lack of response, or judgment of physician
Refractory to last 2-CdA